




































































Gut Microbiome modulation in patients treated with an enriched nutraceutical composition: a multi target strategy
							| Functional Foods in Health and Disease - Online ISSN: 2160-3855; Print ISSN: 2378-7007



	

				
						
 
	Skip to main content
	Skip to main navigation menu
		Skip to site footer


			

				
					
						Open Menu
					
										
																Functional Foods in Health and Disease - Online ISSN: 2160-3855; Print ISSN: 2378-7007
										

				


				
				
					
					
						
																					
				
					Home
				
										
									
										Food Science Publisher
									
								
	
									
										Functional Food Center
									
								


							
	
				
					Current
				
							
	
				
					Archives
				
							
	
				
					About
				
										
									
										About the Journal
									
								
	
									
										Aims and Scope
									
								
	
									
										Contact
									
								
	
									
										Editing Services
									
								
	
									
										Editorial Team
									
								
	
									
										Express Peer Review
									
								
	
									
										Graphical Abstract
									
								
	
									
										Journal Insights
									
								
	
									
										Privacy Statement
									
								
	
									
										Submissions
									
								


							
	
				
					Announcements
				
							
	
				
					Search
				
							



				

																						
									
										
										Search
									
								

													

					

					
								
				
					Register
				
							
	
				
					Login
				
							



					

				
			

		

						
			
				


			
		
			
				Home
			
			/
		
	
			
				Archives
			
			/
		
	
				
					Vol. 14 No. 12 (2024): December 2024
				
				/
			
	
			
									Research Articles
							
		



	
		  	 

		
	
		Gut Microbiome modulation in patients treated with an enriched nutraceutical composition: a multi target strategy
	


	
	
		

							
					Authors

						
							
								Francesco Natale
							
																																		
	
							
								Chiara Fusco
							
																																		
	
							
								Mirella Limatola
							
																																		
	
							
								Luigi Cante
							
																																		
	
							
								Roberta Alfieri
							
																																		
	
							
								Noemi Mollo
							
																																		
	
							
								Rosa Franzese
							
																																		
	
							
								Saverio D'Elia
							
																																		
	
							
								Giovanni Cimmino
							
																																		


				
			
																	
					
												DOI:
					

					
						
							https://doi.org/10.31989/ffhd.v14i12.1437
						
					
				
			

						
										
					Abstract

					Introduction: The contribution of gut microbiota to health and disease is now well accepted and under continuous investigation. It is the most representative in the body (about 70% of the total) with over 400 different species of microorganisms living there. It is exclusive to each individual and therefore represents a real biological imprint, capable of distinguishing humans from one another.

Gut microbiota works synergically with the host, promoting health by performing protective, metabolic and structural functions. Thus, when a modification of the personal normal gut microbiota composition occurs, a predisposition to develop different diseases may increase. Probiotics are functional food that may modulate gut microbiota stimulating protective bacterial properties and inhibiting detrimental activity. We have previously reported a beneficial effect from the administration of an enriched nutraceutical composition containing probiotics in reducing irritable bowel syndrome-related symptoms and improving metabolic profile by lowering triglycerides. However, if these effects are attributed to gut microbiota remain unknown.

Objective: This analysis aims at evaluating microbiota modulation in subjects before and after Triobiotix® administration using a metagenomic approach 

Methods: Triobiotix® is an enriched nutraceutical composition containing maltodextrin, hyaluroic acid and mineralized seaweed extract Lithothamnion Calcareum plus a mix of five different lactic bacterial species. A total of 46 subjects with availability of sample test before and after treatment were included in the present analysis selected from 265 subjects. A fecal sample was collected before and up to 90 days after the administration of Triobiotix®. Feces were analyzed by Wellmicro® gut test that uses the next-generation sequencing of the 16S rRNA gene on Illumina MiSeq. Additionally, for 171 subjects a 90-day clinical evaluation was available.

Results: Treatment with this enriched nutraceutical for up to 3 months resulted in a positive modulation of the main indices of improved gut microbiota, such as biodiversity and dysbiosis. Improvement on metabolic functions, such as glycemic and lipid metabolisms, as well as on immunological and anti-inflammatory activities have been described, thus indicating that the observed clinical benefits associated with the administration of this nutraceutical formulation might be also attributed to a gut microbiota modulation. Improvement in main IBS-related symptoms and bloating was maintained up to 90 days as well as microbiota diversity.

Conclusions: Our analysis suggests that the gut microbiota of subjects taking Triobiotix® rapidly returns to a high diversity with reduced dysbiosis after treatment with associated improvement of main physiological functions linked to brain, heart and liver. 

Keywords: gut microbiota; microbiome, metagenomic; Nutraceuticals 

				
			
			

						
																																																																											
						
		


		

						
										
					
						Downloads
					

						
								
	
													


		
	[Abstract]

	
							
	
								
	
													


		
	[Full Article]

	
							


				

						
						
				
					
						Published
					

					
																			2024-12-03
																	

				
							

			
						
										

											
							
								Issue
							

							
								
									Vol. 14 No. 12 (2024): December 2024
								
							

						
					
											
							
								Section
							

							
								Research Articles
							

						
					
									

			
						
										
					
						License
					

																										Copyright (c) 2024 Functional Foods in Health and Disease

														This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

																Authors retain the copyright of their articles and grant the Functional Food Center (FFC) and its journals the right of first publication under the terms of the Creative Commons Attribution 4.0 International License.

This license permits unrestricted use, distribution, and reproduction in any medium, including commercial use, provided the original author(s) and source are properly credited. Authors may post and share their published work freely, provided that the original publication in this journal is acknowledged.

By submitting to this journal, authors confirm that their manuscripts are original, not under consideration elsewhere, and that they hold the necessary rights to grant this license. The Functional Food Center encourages open scientific exchange and allows derivative and extended works, provided attribution to the original publication is maintained.

				

			
			

		

	




	




	


							



	

	

					
				About the Journal      Editing Services      Graphical Abstract      Journal Insights        Submissions        Editorial Team       Privacy Statement        Contact        Current        Archives

 

			

		
		Open Journal Systems Hosting and Support by: OpenJournalSystems.com


	










